Differences in the sensitivity of ovarian cancer to photodynamic therapy and the mechanisms for those differences

Yokoyama,Yoshihito; Shigeto,Tatsuhiko; Miura,Rie; Kobayashi,Asami; Mizunuma,Makito; Yamauchi,Aisa; Futagami,Masayuki; Mizunuma,Hideki

doi:10.3892/ol.2017.6095

Differences in the sensitivity of ovarian cancer to photodynamic therapy and the mechanisms for those differences

Authors:
- Yoshihito Yokoyama
- Tatsuhiko Shigeto
- Rie Miura
- Asami Kobayashi
- Makito Mizunuma
- Aisa Yamauchi
- Masayuki Futagami
- Hideki Mizunuma
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan
Published online on: April 25, 2017 https://doi.org/10.3892/ol.2017.6095
Pages: 4933-4938

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protoporphyrin IX (PpIX) levels are crucial to the antitumor action of photodynamic therapy (PDT). In the present study, the underling molecular mechanisms for the variation in PpIX levels in ovarian cancer cells were investigated. Five ovarian cancer cell lines were subcutaneously grafted onto the backs of nude mice. Once tumors had developed, 5‑aminolevulinic acid methyl ester hydrochloride (methyl‑ALA) was administered intraperitoneally and the tumor was irradiated twice/week. PpIX levels in the tumor were assayed using high‑performance liquid chromatography. Enzymes involved in heme synthesis and degradation were screened using a microarray technique. Expression of the glutathione transferase Omega‑1 (GSTO1) gene involved in the conversion of PpIX into heme in cells was quantified using the reverse transcription‑quantitative polymerase chain reaction. In HTOA, HRA and DISS cells, PDT resulted in significant tumor shrinkage in comparison with the controls. In MCAS and TOV21G cells, no significant alterations in tumor growth were identified compared with the untreated cells. PpIX levels increased significantly in HTOA, DISS and HRA cells compared with in MCAS and TOV21G cells. A comparison of genetic profiles using PDT‑sensitive DISS cells and PDT‑resistant MCAS cells indicated that MCAS cells exhibited significantly increased levels of δ‑aminolevulinate synthase (a rate‑limiting enzyme in heme synthesis), heme oxygenase 2 (an enzyme that degrades heme into biliverdin), and biliverdin reductase B (an enzyme that reduces biliverdin into bilirubin) in comparison with DISS cells. The level of GSTO1 expression in HTOA, HRA and DISS cells was ~2.5‑fold that in MCAS and TOV21G cells. Sensitivity to PDT is related to PpIX levels in cells. The results of the present study suggested that PpIX tends not to accumulate in PDT‑resistant cells despite active heme synthesis and degradation, and that high levels of GSTO1 expression are associated with increased sensitivity to PDT.

View Figures

View References

1	Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, van Gorp T, Trillsch F, Mahner S, Ulmer H, et al: The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma-analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 131:15–20. 2013. View Article : Google Scholar : PubMed/NCBI
2	Akeson M, Zetterqvist BM, Dahllöf K, Brännström M and Horvath G: Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: A population-based cohort study of all patients in western Sweden with long-term follow-up. Acta Obstet Gynecol Scand. 87:1343–1352. 2008. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
4	Casson AG: Photofrin PDT for early stage esophageal cancer: A new standard of care? Photodiagnosis Photodyn Ther. 6:155–156. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ikeda N, Usuda J, Kato H, Ishizumi T, Ichinose S, Otani K, Honda H, Furukawa K, Okunaka T and Tsutsui H: New aspects of photodynamic therapy for central type early stage lung cancer. Lasers Surg Med. 43:749–754. 2011. View Article : Google Scholar : PubMed/NCBI
6	Spinelli P, Dal Fante M and Mancini A: Current role of laser and photodynamic therapy in gastrointestinal tumors and analysis of a 10-year experience. Semin Surg Oncol. 8:204–213. 1992. View Article : Google Scholar : PubMed/NCBI
7	Choi MC, Lee C and Kim SJ: Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia: A systemic review. Photodiagnosis Photodyn Ther. 11:479–480. 2014. View Article : Google Scholar : PubMed/NCBI
8	Dougherty TJ, Lawrence G, Kaufman JH, Boyle D, Weishaupt KR and Goldfarb A: Photoradiation in the treatment of recurrent breast carcinoma. J Natl Cancer Inst. 62:231–237. 1979.PubMed/NCBI
9	Wakui M, Yokoyama Y, Wang H, Shigeto T, Futagami M and Mizunuma H: Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers. J Cancer Res Clin Oncol. 136:1143–1150. 2010. View Article : Google Scholar : PubMed/NCBI
10	Furuyama K, Harigae H, Kinoshita C, Shimada T, Miyaoka K, Kanda C, Maruyama Y, Shibahara S and Sassa S: Late-onset X-linked sideroblastic anemia following hemodialysis. Blood. 101:4623–4624. 2003. View Article : Google Scholar : PubMed/NCBI
11	Kikuchi Y, Kizawa I, Oomori K, Miyauchi M, Kita T, Sugita M, Tenjin Y and Kato K: Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res. 47:592–596. 1987.PubMed/NCBI
12	Wetterberg L: Acute porphyria and lead poisoning. Lancet. 1:4981966. View Article : Google Scholar : PubMed/NCBI
13	Ho PS, Hoffman BM, Kang CH and Margoliash E: Control of the transfer of oxidizing equivalents between heme iron and free radical site in yeast cytochrome c peroxidase. J Biol Chem. 1258:4356–4363. 1983.
14	Kodym R, Calkins PR and Story MD: Anthracycline-induced erythroid differentiation of K562 cells is inhibited by p28, a novel mammalian glutathione-binding stress protein. Leuk Res. 25:151–156. 2001. View Article : Google Scholar : PubMed/NCBI
15	Paiva L, Hernández A, Martínez V, Creus A, Quinteros D and Marcos R: Association between GSTO2 polymorphism and the urinary arsenic profile in copper industry workers. Environ Res. 110:463–468. 2010. View Article : Google Scholar : PubMed/NCBI
16	Hofer T, Wenger RH, Kramer MF, Ferreira GC and Gassmann M: Hypoxic up-regulation of erythroid 5-aminolevulinate synthase. Blood. 101:348–350. 2003. View Article : Google Scholar : PubMed/NCBI
17	Solár P, Koval J, Mikes J, Kleban J, Solárová Z, Lazúr J, Hodorová I, Fedorocko P and Sytkowski AJ: Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells. Mol Cancer Ther. 7:2263–2271. 2008. View Article : Google Scholar : PubMed/NCBI
18	Jung KA, Choi BH and Kwak MK: The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression. Mol Pharmacol. 87:465–476. 2015. View Article : Google Scholar : PubMed/NCBI
19	Luna MC, Wong S and Gomer CJ: Photodynamic therapy mediated induction of early response genes. Cancer Res. 54:1374–1380. 1994.PubMed/NCBI
20	Meng F, Zhang Y, Liu F, Guo X and Xu B: Characterization and mutational analysis of omega-class GST (GSTO1) from Apis cerana cerana, a gene involved in response to oxidative stress. PLoS One. 9:e931002014. View Article : Google Scholar : PubMed/NCBI
21	Li Z, Sun L, Lu Z, Su X, Yang Q, Qu X, Li L, Song K and Kong B: Enhanced effect of photodynamic therapy in ovarian cancer using a nanoparticle drug delivery system. Int J Oncol. 47:1070–1076. 2015.PubMed/NCBI
22	Koide Y, Urano Y, Yatsushige A, Hanaoka K, Terai T and Nagano T: Design and development of enzymatically activatable photosensitizer based on unique characteristics of thiazole orange. J Am Chem Soc. 131:6058–6059. 2009. View Article : Google Scholar : PubMed/NCBI